Posted by Michael Wonder on 07 Sep 2018
Pfizer receives breakthrough therapy designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with alopecia areata
5 September 2018 - Phase II data accepted for late-breaker news session at 2018 EADV Congress.
Pfizer today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received breakthrough therapy designation from the U.S. FDA for the treatment of patients with alopecia areata, a chronic auto-immune skin disease that causes hair loss on the scalp, face, or body.
The breakthrough therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology Congress in Paris on 15 September 2018.
